{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T21:32:55Z","timestamp":1770327175744,"version":"3.49.0"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100022840","name":"Serum Institute of India Private Limited","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100022840","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.vaccine.2025.128151","type":"journal-article","created":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T10:50:18Z","timestamp":1766487018000},"page":"128151","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Plaque reduction neutralization test (PRNT50) for the detection of anti-yellow fever antibodies from clinical samples"],"prefix":"10.1016","volume":"73","author":[{"given":"Parikshit","family":"Tyagi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Milan","family":"Ganguly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satyaprasad","family":"Manney","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kuntinath","family":"Wadkar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nilesh","family":"Ingle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sunil","family":"Gairola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rajeev","family":"Dhere","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giulia","family":"Lapini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo","family":"Cantaloni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.vaccine.2025.128151_bb0005","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1001638","article-title":"Yellow fever in Africa: estimating the burden of disease and impact of mass vaccination from outbreak and serological data","volume":"11","author":"Garske","year":"2014","journal-title":"PLOS Med"},{"key":"10.1016\/j.vaccine.2025.128151_bb0010","series-title":"Plotkin\u2019s vaccines","article-title":"Yellow fever vaccines","author":"Staples","year":"2017"},{"key":"10.1016\/j.vaccine.2025.128151_bb0015","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1093\/trstmh\/tru092","article-title":"The whole iceberg: estimating the incidence of yellow fever virus infection from the number of severe cases","volume":"108","author":"Johansson","year":"2014","journal-title":"Trans R Soc Trop Med Hyg"},{"issue":"5","key":"10.1016\/j.vaccine.2025.128151_bb0020","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0004709","article-title":"Characterization of yellow fever virus infection of human and non-human primate antigen presenting cells and their interaction with CD4+ T cells","volume":"10","author":"Cong","year":"2016","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.vaccine.2025.128151_bb0025","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/nmicrobiol.2016.164","article-title":"Cross-reactive antibodies enhance live attenuated virus infection for increased immunogenicity","volume":"1","author":"Chan","year":"2016","journal-title":"Nat Microbiol"},{"key":"10.1016\/j.vaccine.2025.128151_bb0030","doi-asserted-by":"crossref","first-page":"6675","DOI":"10.1073\/pnas.1921388117","article-title":"Longitudinal dynamics of the human B cell response to the yellow fever 17D vaccine","volume":"117","author":"Wec","year":"2020","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2025.128151_bb0035","unstructured":"World Health Organisation Yellow Fever Laboratory Diagnostic Testing in Africa Interim Guidance. WHO\/OHE\/YF\/LAB\/16.1; 2016. Available online from: https:\/\/www.who.int\/publications\/i\/item\/WHO-OHE-YF-LAB-16-1."},{"key":"10.1016\/j.vaccine.2025.128151_bb0040","unstructured":"Pan American Health Organization. Laboratory diagnosis of yellow fever virus infection; 2018. Available online from: https:\/\/www.paho.org\/en\/documents\/laboratory-diagnosis-yellow-fever-virus-infection."},{"key":"10.1016\/j.vaccine.2025.128151_bb0045","unstructured":"Monath TP. Yellow fever vaccine. In: Plotkin S, Orenstein WA, editors. Vaccines. 4th ed. Philadelphia: Elsevier; 2004. 1095e176."},{"key":"10.1016\/j.vaccine.2025.128151_bb0050","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1128\/am.16.11.1770-1775.1968","article-title":"Yellow fever virus. I. Development and evaluation of a plaque neutralization test","volume":"16","author":"Spector","year":"1968","journal-title":"Appl Microbiol"},{"issue":"6","key":"10.1016\/j.vaccine.2025.128151_bb0055","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.biologicals.2012.09.005","article-title":"Evaluation of accuracy and reliability of the plaque reduction neutralization test (micro-PRNT) in detection of yellow fever virus antibodies","volume":"40","author":"Sim\u00f5es","year":"2012","journal-title":"Biologicals"},{"issue":"1","key":"10.1016\/j.vaccine.2025.128151_bb0060","first-page":"113","article-title":"A simple micro-culture method for the study of group B arboviruses","volume":"40","author":"De Madrid","year":"1969","journal-title":"Bull World Health Organ"},{"issue":"12","key":"10.1016\/j.vaccine.2025.128151_bb0065","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1046\/j.1365-3156.1999.00496.x","article-title":"Assessment of IgG antibodies against yellow fever virus after vaccination with 17D by different assays: neutralization test, hemagglutination inhibition test, immunofluorescence assay and ELISA","volume":"4","author":"Niedrig","year":"1999","journal-title":"Trop Med Int Health"},{"issue":"2","key":"10.1016\/j.vaccine.2025.128151_bb0070","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1089\/vim.2008.0007","article-title":"Guidelines for plaque-reduction neutralization testing of human antibodies to dengue viruses","volume":"21","author":"Roehrig","year":"2008","journal-title":"Viral Immunol"},{"key":"10.1016\/j.vaccine.2025.128151_bb0075","article-title":"Viral concentration determination through plaque assays: using traditional and novel overlay systems","volume":"93","author":"Baer","year":"2014","journal-title":"J Vis Exp"},{"issue":"1","key":"10.1016\/j.vaccine.2025.128151_bb0080","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.jviromet.2012.09.026","article-title":"Assessment of plaque assay methods for alphaviruses","volume":"187","author":"Juarez","year":"2013","journal-title":"J Virol Methods"},{"key":"10.1016\/j.vaccine.2025.128151_bb0085","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.coi.2009.05.018","article-title":"Yellow fever vaccine - how does it work and why do rare cases of serious adverse events take place?","volume":"21","author":"Barrett","year":"2009","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.vaccine.2025.128151_bb0090","series-title":"Yellow fever vaccine","first-page":"870","author":"Monath","year":"2012"},{"key":"10.1016\/j.vaccine.2025.128151_bb0095","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1128\/jvi.22.3.608-618.1977","article-title":"Antigenic characterization of Flavivirus structural proteins separated by isoelectric focusing","volume":"22","author":"Trent","year":"1977","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2025.128151_bb0100","doi-asserted-by":"crossref","first-page":"13975","DOI":"10.1128\/JVI.78.24.13975-13986.2004","article-title":"Localization and characterization of Flavivirus envelope glycoprotein cross-reactive epitopes","volume":"78","author":"Crill","year":"2004","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2025.128151_bb0105","doi-asserted-by":"crossref","first-page":"9557","DOI":"10.1128\/JVI.00080-06","article-title":"Cryptic properties of a cluster of dominant Flavivirus cross-reactive antigenic sites","volume":"80","author":"Stiasny","year":"2006","journal-title":"J Virol"},{"issue":"1","key":"10.1016\/j.vaccine.2025.128151_bb0110","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/0042-6822(88)90406-0","article-title":"Nucleotide sequence of dengue 2 RNA and comparison of the encoded proteins with those of other flaviviruses","volume":"162","author":"Hahn","year":"1988","journal-title":"Virology"},{"issue":"10","key":"10.1016\/j.vaccine.2025.128151_bb0115","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1002\/jmv.22180","article-title":"Acute West Nile virus neuroinvasive infections: cross-reactivity with dengue virus and tick-borne encephalitis virus","volume":"83","author":"Papa","year":"2011","journal-title":"J Med Virol"},{"issue":"2","key":"10.1016\/j.vaccine.2025.128151_bb0120","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1590\/S0124-00642008000200010","article-title":"Dengue-yellow fever sera cross-reactivity; challenges for diagnosis","volume":"10","author":"Houghton-Trivi\u00f1o","year":"2008","journal-title":"Revistade Salud P\u00fablica"},{"key":"10.1016\/j.vaccine.2025.128151_bb0125","doi-asserted-by":"crossref","first-page":"739","DOI":"10.4269\/ajtmh.2011.10-0496","article-title":"Description of a prospective 17DD yellow fever vaccine cohort in Recife, Brazil","volume":"85","author":"de Melo","year":"2011","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.vaccine.2025.128151_bb0130","doi-asserted-by":"crossref","first-page":"230","DOI":"10.4269\/ajtmh.1963.12.230","article-title":"Immunological studies with group B arthropod-borne viruses. IV. Persistence of yellow fever antibodies following vaccination with 17D strain yellow fever vaccine","volume":"12","author":"Rosenzweig","year":"1963","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.vaccine.2025.128151_bb0135","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1586\/14760584.4.4.553","article-title":"Yellow fever vaccine","volume":"4","author":"Monath","year":"2005","journal-title":"Expert Rev Vaccines"},{"issue":"Pt 1","key":"10.1016\/j.vaccine.2025.128151_bb0140","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1099\/0022-1317-70-1-37","article-title":"Antigenic relationships between flaviviruses as determined by cross-neutralization tests with polyclonal antisera","volume":"70","author":"Calisher","year":"1989","journal-title":"J Gen Virol"},{"issue":"5","key":"10.1016\/j.vaccine.2025.128151_bb0145","doi-asserted-by":"crossref","first-page":"962","DOI":"10.4269\/ajtmh.12-0461","article-title":"Optimization and validation of a plaque reduction neutralization test for the detection of neutralizing antibodies to four serotypes of dengue virus used in support of dengue vaccine development","volume":"88","author":"Timiryasova","year":"2013","journal-title":"Am J Trop Med Hyg"},{"issue":"2","key":"10.1016\/j.vaccine.2025.128151_bb0150","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0262149","article-title":"FluoRNT: a robust, efficient assay for the detection of neutralising antibodies against yellow fever virus 17D","volume":"17","author":"Scheck","year":"2022","journal-title":"PLoS ONE"},{"issue":"10269","key":"10.1016\/j.vaccine.2025.128151_bb0155","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S0140-6736(20)32520-4","article-title":"Immunogenicity and safety of fractional doses of yellow fever vaccines: a randomised, double-blind, non-inferiority trial","volume":"397","author":"Juan-Giner","year":"2021","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.vaccine.2025.128151_bb0160","doi-asserted-by":"crossref","DOI":"10.1002\/jmv.28700","article-title":"Performance assessment and validation of a plaque reduction neutralization test (PRNT) in support to yellow fever diagnostic and vaccine clinical trials","volume":"95","author":"Dia","year":"2023","journal-title":"J Med Virol"},{"issue":"7","key":"10.1016\/j.vaccine.2025.128151_bb0165","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0009557","article-title":"Target product profile for a dengue pre-vaccination screening test","volume":"15","author":"Fongwen","year":"2021","journal-title":"PLoS Negl Trop Dis"},{"issue":"8","key":"10.1016\/j.vaccine.2025.128151_bb0170","doi-asserted-by":"crossref","DOI":"10.1099\/acmi.0.000257","article-title":"Performance comparison of micro-neutralization assays based on surrogate SARS-CoV-2 and WT SARS-CoV-2 in assessing virus-neutralizing capacity of anti-SARS-CoV-2 antibodies","volume":"3","author":"Sekirov","year":"2021","journal-title":"Access Microbiol"},{"issue":"3","key":"10.1016\/j.vaccine.2025.128151_bb0175","doi-asserted-by":"crossref","DOI":"10.1128\/Spectrum.00886-21","article-title":"Evaluating humoral immunity against SARS-CoV-2: validation of a plaque-reduction neutralization test and a multilaboratory comparison of conventional and surrogate neutralization assays","volume":"9","author":"Valcourt","year":"2021","journal-title":"Microbiol Spectr"},{"issue":"1","key":"10.1016\/j.vaccine.2025.128151_bb0180","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/s41541-022-00595-6","article-title":"A phase I clinical study to assess safety and immunogenicity of yellow fever vaccine","volume":"7","author":"Desai","year":"2022","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.vaccine.2025.128151_bb0185","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1186\/1471-2334-12-233","article-title":"Variation in dengue virus plaque reduction neutralization testing: systematic review and pooled analysis","volume":"12","author":"Rainwater-Lovett","year":"2012","journal-title":"BMC Infect Dis"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X25014495?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X25014495?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T09:03:21Z","timestamp":1770282201000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X25014495"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":37,"alternative-id":["S0264410X25014495"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2025.128151","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Plaque reduction neutralization test (PRNT50) for the detection of anti-yellow fever antibodies from clinical samples","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2025.128151","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"128151"}}